KEAP1 and neoplasm: Moreover, co-mutations in KEAP1 and TP53 exacerbate these effects, promoting aggressive tumor phenotypes characterized by enhanced antioxidant defenses, metabolic reprogramming, and increased resistance to oxidative damage [149].